Development of a high-producing cell line supported by a robust upstream process are critical early steps in the production of monoclonal antibodies (mAbs). Optimization of this upstream workflow is essential to deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic. Historically, many of the steps used to identify clones and then scale the production process have been time-consuming and labor-intensive – slowing progress right from the starting gate.
This whitepaper describes the integration of technologies to more rapidly identify high-producing cell lines, strategies to optimize media feeds and a robust bioreactor scale-up approach to create a consistent and reliable solution for upstream bioprocess development.
